Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The key role of stem cell factor/KIT signaling in the proliferation of blast cells from Down syndrome-related leukemia.

Leukemia - 1 Jan 2009

Toki T, Kanezaki R, Adachi S, Fujino H, Xu G, Sato T, Suzuki K, Tauchi H, Endo M, Ito E

Abstract excerpt

Transient leukemia (TL) has been observed in approximately 10% of newborn infants with Down syndrome (DS). Although treatment with cytarabine is effective in high-risk TL cases, approximately 20% of severe patients still suffer early death. In this study, we demonstrate abundant KIT expression in all 13 patients with GATA1 mutations, although no significant difference in expression levels was observed between TL...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Down Syndrome
Share to GATA1 Transcription Factor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Leukemia

Share to Piperazines

Share to Pyrimidines

Share to Stem Cell Factor

Source

Identifiers

PMID: 18830255
DOI: 10.1038/leu.2008.267

Genes

KIT
GATA1
MCL1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The key role of stem cell factor/KIT signaling in the proliferation of blast cells from Down syndrome-related leukemia.PMID 18830255Read ↗

Advances in molecular characterization of myeloid proliferations associated with Down syndromeSemantic proximity Read ↗

Clinical and biological aspects of myeloid leukemia in Down syndrome.Semantic proximity Read ↗

Modeling Down Syndrome Myeloid Leukemia by Sequential Introduction of GATA1 and STAG2 Mutations in Induced Pluripotent Stem Cells with Trisomy 21.Semantic proximity Read ↗

Down syndrome and leukemia: insights into leukemogenesis and translational targets.Semantic proximity Read ↗

Recent advances in the understanding of transient abnormal myelopoiesis in Down syndromeSemantic proximity Read ↗

Acute megakaryoblastic leukemia with acquired trisomy 21 and GATA1 mutations in phenotypically normal children.Semantic proximity Read ↗

The biology of pediatric acute megakaryoblastic leukemiaSemantic proximity Read ↗

GATA1 mutations in Down syndrome: implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia.Semantic proximity Read ↗

Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.Semantic proximity Read ↗

Exome sequencing identifies putative drivers of progression of transient myeloproliferative disorder to AMKL in infants with Down syndrome.Semantic proximity Read ↗

Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesisSemantic proximity Read ↗

Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.